ENDO Online 2020 Product Theaters

July 10, 2020

NP Thyroid® (Thyroid Tablets, USP): Understanding the Options for Management of Hypothyroidism

For the majority of patients seeking treatment for hypothyroidism and Hashimoto’s thyroiditis, levothyroxine (LT4) monotherapy is the recommended first line treatment. However, many patients remain symptomatic despite achieving normal lab values and thyroid function tests. There is a growing body of clinical evidence that suggests certain subsets of patients with hypothyroidism, such as those with genetic polymorphisms of the D2 deiodinase gene, may benefit from combination therapy with both T4 and T3. This product theater will provide a synopsis of the management of hypothyroidism with combination therapy as well as an overview of NP Thyroid, which is a natural desiccated porcine thyroid extract containing both T4 and T3 indicated for thyroid hormone replacement in hypothyroidism and Hashimoto’s thyroiditis.

Gary M. Pepper, MD
Palm Beach Diabetes & Endocrine Specialists
Palm Beach, FL

Sponsored by Acella Pharmaceuticals


The Next Generation of the Guardian™ Connect Continuous Glucose Monitoring System: Accuracy When it Matters Most with Real World Outcomes

Introduction to the new Guardian™ Connect CGM app, featuring even more customizable prediction, easier onboarding, and new CareLink™ reports for your practice. Please join us to learn more about the system and the different measures of accuracy, with real world outcomes and case studies demonstrating the integration of CareLink™ reports to help you manage your patients on multiple daily injections.

Bruce Bode, MD

Sponsored by Medtronic


A Paradigm Shift for the Management of Thyroid Eye Disease (TED)

Come learn about the importance of early identification and a new treatment approach for Thyroid Eye Disease (TED) management. This presentation is intended for US-based healthcare professionals.

Raymond S. Douglas, MD, PhD
Professor of Ophthalmology
Director, Orbital and Thyroid Eye Disease Center
Cedars-Sinai Medical Center, Los Angeles, CA

Terry J. Smith, MD

Frederick G.L. Huetwell
Professor of Ophthalmology and Visual Sciences
Professor, Department of Internal Medicine
Kellogg Eye Center
University of Michigan Medical School, Ann Arbor, MI

Sponsored by Horizon Therapeutics


Enabling Telemedicine and Remote Monitoring with the FreeStyle Libre 14 day System

Join us to learn about the #1 CGM worldwide† used by more than 2 million people*, the FreeStyle Libre 14 day system.

Daniel Einhorn, M.D., FACP, FACE will share how he utilizes the FreeStyle Libre 14 day system to enable diabetes management and monitoring of patients remotely. He will also share real-world telemedicine patient cases.

Daniel Einhorn, MD, FACP, FACE
Medical Director, Scripps Whittier Diabetes Institute
Clinical Professor of Medicine, University of California, San Diego
President, Diabetes and Endocrine Associates

†Data based on the number of users worldwide for FreeStyle Libre personal CGM compared to the number of users for other leading personal CGM brands.

*Data based on the number of users worldwide for FreeStyle Libre products. In the United States product is branded FreeStyle Libre 14 day System.

This program is sponsored by Abbott, the speaker or speakers are presenting on behalf of Abbott and the content of the program is in compliance with applicable regulatory requirements.


Clinical Management of Adrenocortical Carcinoma (ACC)

Adrenocortical Carcinoma (ACC) is a rare endocrine tumor with a poor prognosis that requires a multi-disciplinary approach between endocrinologists, oncologists and surgeons. The presentation will focus on the diagnosis, prognosis and current treatment guidelines for ACC patients.

Mouhammed Amir Habra, MD, F.A.C.P., F.A.C.E.
Associate Professor, Deptartment of Endocrine Neoplasia and Hormonal Disorders
MD Anderson Cancer Center, Houston, TX

Sponsored by HRA Pharma Rare Diseases


Precision Medicine in Skeletal Dysplasias: Genetics, Pathophysiology, & Investigational Approaches to Therapy

More than 400 skeletal dysplasias have a genetic basis of disease identified. Currently, these patients may experience lifelong, progressive, multisystemic comorbidities. This on-demand presentation, moderated by Dr. Ron Rosenfeld, brings together 4 experts who will discuss the genetic basis of skeletal dysplasias, their pathophysiology, and the development of investigational therapies for achondroplasia.

Chair and Presenter:
Ron Rosenfeld, MD
Pediatric Endocrinologist
Professor and Chair (emeritus) of Pediatrics
Oregon Health and Science University

Julie Hoover-Fong, MD, PhD
Clinical Geneticist
Greenberg Center for Skeletal Dysplasias
McKusick-Nathans Department of Genetic Medicine
Johns Hopkins University, Baltimore, MD

Nadia Merchant, MD
Pediatric Endocrinologist & Clinical Geneticist
Children’s National Hospital, Washington, DC

Bradley S. Miller, MD, PhD
Division of Endocrinology
Department of Pediatrics
University of Minnesota Masonic Children’s Hospital, Minneapolis, MN

Sponsored by BioMarin Pharmaceuticals


Finally, an Oral Testosterone Replacement Therapy for Men with Hypogonadism

Join us for an overview of an FDA-approved and available oral testosterone replacement therapy. During this program, an expert will discuss the history and challenges of TRTs, and the pathway to approval for this oral option, as well as its safety and efficacy profiles.

Paresh Dandona MD, PhD
State University of New York at Buffalo, Buffalo, New York

Sponsored by Clarus Therapeutics

Last Updated:
Back to top

Who We Are

For 100 years, the Endocrine Society has been at the forefront of hormone science and public health. Read about our history and how we continue to serve the endocrine community.